AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2020
Dec 12, 2020
31900_dirs_2020-12-11_f4e6ef7a-3b4f-4357-a184-321af860c279.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2020-12-05
Reporting Person: Moran Kyle (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 20084 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Share Option (Right to Buy) | $2.48 | 2025-03-10 | Ordinary Shares (35930) | Direct | |
| Share Option (Right to Buy) | $18.79 | 2026-06-16 | Ordinary Shares (21647) | Direct | |
| Share Option (Right to Buy) | $40.05 | 2028-01-23 | Ordinary Shares (15000) | Direct | |
| Share Option (Right to Buy) | $8.17 | 2030-03-03 | Ordinary Shares (36000) | Direct |
Footnotes
F1: Consists of 8,609 ordinary shares; 2,100 restricted share units (RSUs) that vest in four equal annual installments beginning on February 1, 2018 through February 1, 2021; 3,750 RSUs that vest in four equal annual installments of 25% beginning on February 15, 2019 through February 15, 2022; and 5,625 RSUs that vest in four equal annual installments of 25% beginning on February 15, 2020 through February 15, 2023.
F2: The option vests as to 25% of the shares on July 1, 2015 and vests as to an additional 2.0833% of the shares monthly thereafter until July 1, 2018.
F3: The option vests as to 25% of the shares on June 16, 2017 and vests as to an additional 2.0833% of the shares quarterly thereafter until June 16, 2020.
F4: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022.
F5: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022.